ALFA Filings
Every announcement, straight from the exchange
Every Bharat Parenterals business update announcement on NSE and BSE, newest first, each with its own page.
Time
2 announcements with these filters
Innoxel Lifesciences, a Bharat Parenterals subsidiary, began U.S. commercial supply of its first CMO product. This adds recurring manufacturing revenue to its existing licensing income.
Bharat Parenterals Limited's subsidiary, Innoxel Lifesciences, concluded a U.S. FDA inspection at its Vadodara facility with five procedural observations under a Voluntary Action Indicated (VAI) classification. The inspection occurred in April 2026. The company maintains its commitment to quality standards and will submit responses within prescribed timelines.